Core binding factor (CBF) is a heterodimer protein complex involved in the transcriptional regulation of normal hematopoietic process. In addition, CBF molecular aberrations represent approximately 20% of all adult Acute Myeloid Leukemia (AML) patients. Treated with standard therapy, adult CBF AML has higher complete remission (CR) rate, longer CR duration, and better prognosis than that of AML patients with normal karyotype or other chromosomal aberrations. Although the prognosis of CBF AML is better than other subtypes of adult AML, it is still a group of heterogeneous diseases, and the prognosis is often different. Recurrence and relapse-related death are the main challenges to be faced following treatment. Mounting research shows the gene heterogeneity of CBF AML. Therefore, to achieve an improved clinical outcome, the differences in clinical and genotypic characteristics should be taken into account in the evaluation and management of such patients, so as to further improve the risk stratification of prognosis and develop targeted therapy. The present article is a comprehensive review of the differences in some common mutant genes between two subtypes of CBF AML.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7366242 | PMC |
| http://dx.doi.org/10.3892/mco.2020.2052 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Clinical characteristics and treatment efficacy of newly diagnosed acute leukemia in the plateau].
Zhonghua Xue Ye Xue Za Zhi
December 2024
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China.
This study aimed to retrospectively analyze the clinical characteristics and prognosis of patients with acute leukemia in the plateau. The clinical information of patients diagnosed with acute leukemia from February 2010 to April 2023 at the People's Hospital of Tibet Autonomous Region was reviewed and collected, including blood cell count, morphology, immunophenotype, cytogenetics, and molecular data. Survival analysis was conducted to analyze the outcome of patients with acute leukemia.
View Article and Find Full Text PDFThe prognostic significance of genetics in acute myeloid leukemia under venetoclax-based treatment.
Ann Hematol
December 2024
Department of Hematology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, 310022, China.
Acute myeloid leukemia (AML) is the most prevalent hematologic malignancy in adults. In 2022, the European LeukemiaNet (ELN) has updated its prognostic system that incorporates cytogenetics and molecular genetics based on data from patients undergoing intensive chemotherapy (IC). Recently, a risk stratification framework has been established for hypomethylating agents (HMA)-based low-intensity treatment (LIT) to fill the gaps in stratification for this treatment modality, but this needs further refinement.
View Article and Find Full Text PDFThe Functional and Prognostic Impact of TIGIT Expression on Bone Marrow NK Cells in Core Binding Factor-Acute Myeloid Leukemia Patients at Diagnosis.
Biomedicines
September 2024
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China.
: The effect of the expression of the newly identified immune checkpoint, T cell immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain (TIGIT) on NK cells in core binding factor-acute myeloid leukemia (CBF-AML) remains to be investigated. : Fresh bone marrow samples from a total of 39 newly diagnosed CBF-AML patients and 25 healthy donors (HDs) were collected for testing the phenotype and function state of total NK, CD56, and CD56 NK cell subsets after in vitro stimulation. : The frequencies of TIGIT cells in total NK, CD56, and CD56 NK cell subsets had no significant difference between patients and HDs.
View Article and Find Full Text PDFLong-term survival can be achieved in a significant fraction of older patients with core binding factor acute myeloid leukemia treated with intensive chemotherapy.
Haematologica
October 2024
Oncohematology, Dept. Of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua.
Article Synopsis
- - The study analyzed data from 229 elderly patients with core binding factor acute myeloid leukemia (CBF-AML) to assess treatment outcomes over two decades, finding a 5-year overall survival (OS) rate of 44.2% and event-free survival (EFS) rate of 32.9%.
- - In patients over 70 who underwent intensive therapy, those who completed treatment had a median EFS of 11.8 months and a 5-year OS of 40%.
- - Key factors impacting survival included age, achieving remission after initial treatment, and the number of consolidation therapy cycles, indicating that intensive therapy could be beneficial for selected older patients and should not be overlooked in clinical studies. *
Clinical features and long-term outcomes of pediatric patients with de novo acute myeloid leukemia in China with or without specific gene abnormalities: a cohort study of patients treated with BCH-AML 2005.
Hematology
December 2024
Department of Clinical Laboratory Center, Key Laboratory of Major Diseases in Children Ministry of Education, Beijing Children's Hospital Capital Medical University, National Center for Children's Health, Beijing, People's Republic of China.
Acute myeloid leukemia (AML), which has distinct genetic abnormalities, has unique clinical and biological features. In this study, the incidence, clinical characteristics, induction treatment response, and outcomes of a large cohort of Chinese AML pediatric patients treated according to the BCH-AML 2005 protocol were analyzed. was the most common fusion transcript, followed by the and rearrangements.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!